We are led by an executive team with deep expertise and experience in biopharmaceuticals. Our team has held successful and diverse roles at leading organizations and have been involved in the discovery and development as well as approval and commercialization of multiple, innovative therapeutic products.
Tahir Mahmood, PhD
Chief Executive Officer & Co-Founder
Tahir co-founded AMT, where he has overseen the company’s growth from concept to clinical trials in patients through multiple equity financing rounds. He was closely involved in the early development of the technology and also led the company’s partnering and corporate development activities.
With a career that has straddled science and business, Tahir previously led the US West Coast Life Sciences consulting practice at Booz Allen Hamilton and was Managing Director at Lake Sherwood Partners. As a consultant, he advised executives across the spectrum of life sciences, healthcare provider, private and public equity investment, and global health organizations.
Tahir is also co-founder and director of MiNDERA, a non-invasive skin genomics company with a technology platform he co-invented and developed as an investigator at The Scripps Research Institute. He served as Principal Business Analyst at Amgen, supporting business development, M&A and strategic venture fund transactions. Earlier, he was at Chienna (acquired by OctoPlus) and IsoTis S.A. (acquired by Integra Life Sciences). Tahir has authored numerous peer-reviewed publications and is inventor on issued and pending patents. He received BASc and MSc degrees from the University of Toronto. He holds a PhD in Chemical & Biomedical Engineering from a collaborative program between the University of Twente (The Netherlands) and Massachusetts Institute of Technology at the Harvard-MIT Division of Health Sciences and Technology and Boston Children’s Hospital.
Randall Mrsny, PhD
Chief Scientific Officer & Co-Founder
An epithelial biologist, Randy has more than three decades of industry and academic experience in pharmaceutical sciences and research into the mucosal trafficking of peptide and protein therapeutics.
He has overseen the development of AMT’s core molecular transport and targeting platforms and leads the company’s Platform Strategies Group that is advancing tools and applications for the underlying technology. Previously, he led research groups at Genentech (Drug Delivery/Biology) and ALZA (Peptide Biology), and holds an academic position at the University of Bath (UK), where he took the Professor’s Chair of Epithelial Cell Biology.
Randy has served as an advisor to governments and multinational agencies and is the recipient of many awards and commendations, including being elected as President and to the College of Fellows of the Controlled Release Society (CRS) and in 2019 was awarded the Founders Award by the CRS for his contributions to the field.
Randy obtained a BS in Biochemistry and Biophysics at the University of California at Davis, a PhD in Anatomy and Cell Biology at the U.C. Davis School of Medicine, and was a NIH Postdoctoral Fellow in Membrane Biophysics in the Institute of Molecular Biology at the University of Oregon.
Chief Business and Strategy Officer
Liz joined AMT to lead multiple business functions, including Corporate Development and Strategy, Alliance Management, Portfolio Strategy and Project Management, and Commercial Development. Liz brings more than twenty-five years of biotech and pharmaceutical company experience, including roles in corporate development, corporate strategy, and commercial strategy.
Liz most recently held the positions of Chief Operating Officer and Chief Business Officer at Achaogen where she led in-licensing, out-licensing and acquisitions, alliance management and government grants, in addition to holding operational responsibilities.Prior to Achaogen, Liz was VP, Corporate Development at Gilead Sciences where she was responsible for leading teams to execute licenses, acquisitions and collaborations across all of Gilead’s therapeutic areas, which included transactions for filgotinib (Galapagos), firsocostat (Nimbus) and Yescarta (Kite Pharma). During her time at Gilead, she also led long-term global commercial and strategic planning for Gilead’s HIV, HepB, HepC, and respiratory franchises and supported the launch of several products. Liz also held corporate development and strategy roles at Eli Lilly and Maxygen and started her career in research at Affymax. Liz earned a BA in Chemistry from Pomona College, a MS in Biomedical Sciences from UC San Diego, and an MBA from the Kellogg School of Management at Northwestern University.
Chief Financial Officer
Shawn joined AMT as chief financial officer in 2020 where he leads the company’s finance strategy and oversees financial operations. He brings over 20 years of biopharmaceutical strategic advisory and capital market experience. Prior to joining AMT, Mr. Cross was at JMP Securities where he served as managing director and co-head of healthcare investment banking. Previously, Shawn held various investment banking roles at top financial institutions in New York, London, and San Francisco including managing director in healthcare investment banking at Deutsche Bank Securities, managing director and head of biopharmaceutical investment banking at Wells Fargo Securities, amongst others. He also brings operational experience from his time on the executive management team at GT Biopharma, a targeted immunotherapies company. Shawn holds an M.B.A. from Columbia Business School and a B.S. from the University of California, Los Angeles.
Executive Vice President, General Counsel
Earl joins AMT with over 30 years of experience as an attorney, serving as legal counsel for publicly traded biotech and medical device companies as well as start-ups. In these roles, Earl advised management and Boards on a wide range of legal and strategic matters, including corporate governance, SEC filings, commercial transactions, intellectual property strategy, mergers and acquisitions, corporate finance, litigation, and compliance programs.
Most recently, Earl served as general counsel at Kiverdi. He also served as general counsel and corporate secretary at BioMimetic Therapeutics (acquired by Wright Medical Group), Spinal Dynamics (acquired by Medtronic), and OPX Biotechnologies (acquired by Cargill). He also previously served as Counsel with Wilson Sonsini Goodrich & Rosati, and earlier in his career practiced as an associate with Weil, Gotshal & Manges. Earl holds a Juris Doctor from Columbia University School of Law and a BS in Chemical engineering from the Massachusetts Institute of Technology
Senior Vice President, Finance and Business Operations
Brandon has twenty years of biotechnology experience in various disciplines from both large and small companies. He has held roles in Financial Planning & Analysis, Accounting, Financial Systems, Treasury, Operations Finance, Supply Chain, and Manufacturing. In addition to providing leadership for the Finance and Accounting functions, Brandon oversees all administrative operations for the company. Prior to joining Applied Molecular Transport, Brandon served as Chief Financial Officer at Singulex, an immunodiagnostics company with businesses in life science research, a clinical laboratory and IVD instrumentation. Prior to Singulex, he worked in Business Planning & Analysis at Novartis Vaccines and Diagnostics managing manufacturing and supply chain finance for the diagnostics side of the business. Prior to his time at Novartis, Brandon started his career at Genentech where he held various roles in finance, accounting, and product operations functions. Brandon earned his Bachelor’s degree in Cell and Developmental Biology from the University of California at Santa Barbara and a Master’s degree in Business Administration from the University of San Francisco.
Bittoo Kanwar, MD
Chief Medical Officer
Bittoo leads Clinical Development activities at Applied Molecular Transport, where he is overseeing the current clinical program AMT-101 and developing clinical strategy for the company’s pipeline assets and technology platforms. Previously, Bittoo was VP of Clinical Development at Protagonist Therapeutics where he led programs in Ulcerative Colitis and Crohn’s Disease. He began his industry career at Gilead Sciences where he supported programs in liver fibrosis/NASH, Hepatitis B and C, and served as the Clinical Domain Lead for Inflammatory Bowel Disease. Prior to his career in industry, Bittoo was an adjunct associate professor at UCSF focused on researching the role of the gut adaptive immune response in both HIV infection and IBD. Bittoo obtained his MD from the University of Iowa, completed his residency at Rush University Hospitals in Chicago, and a fellowship in pediatric gastroenterology from UCSF.
Derek Maclean, PhD
Senior Vice President, Pharmaceutical Sciences
Derek is a pharmaceutical scientist with over 20 years of operational and management experience in medicinal chemistry, formulation development, and product manufacturing. Prior to joining Applied Molecular Transport, Derek was Vice-President of Chemistry Research at Relypsa Inc, leading the chemical development of advanced polymer therapeutics. Previously, as Director of Product Engineering at Amgen he led late-stage drug product activities leading to the approval and commercialization of etelcalcetide, which he co-invented and led CMC development as Executive Director of Chemistry and Manufacturing at KAI Pharmaceuticals prior to its acquisition by Amgen. Before KAI he held positions of increasing responsibility at Glaxo, Affymax, and Parke-Davis. He received a PhD in Organic Chemistry from the University of Edinburgh and has more than 25 peer-reviewed publications and over 10 patent filings.
Senior Vice President, Operations
Chuck is a biotechnology industry professional with broad scientific and operational experience, having a focus in process development, manufacturing, and other CMC related activities. With over thirty years of experience, he has enabled the production of virtually every class and size of biological product from recombinant proteins, enzymes, blood products, natural products, adenovirus, and whole cell immunotherapy. He has developed products from preclinical through clinical development and commercial. His background includes leading Process Development, CMC or Technical Operations functions at Anthera, NGM Bio, Coherus, and Cell Genesys. He previously served in senior technical positions at BioMarin, Onyx, Bayer, and Genentech.
Chief Technical Officer
With more than 26 years of experience in the biopharma industry, Mr. Rich brings deep operations and quality experience across the entire product lifecycle. He has served in leadership roles responsible for the development and commercialization of both biopharmaceuticals and small molecules. Mr. Rich most recently served as Senior Vice President Operations at UNITY Biotechnology where he led Technical Operations, Quality, Supply Chain, and Portfolio/Project/Alliance Management. Prior to UNITY, he was Senior Vice President Operations at Kythera Biopharmaceuticals Inc., acquired by Allergan PLC. Prior to Kythera, he was Vice President Quality at Boehringer-Ingelheim working in both the Biopharmaceutical and Prescription Medicine Business Units. Earlier in his career, Mr. Rich also spent over 18 years at Amgen Inc., in various roles within Operations including Global Operations Strategy, Manufacturing, Quality Control, and Site Quality Head.
Andy Whitney, PhD
Vice President, Preclinical Development and Translational Science
Andy leads AMT’s preclinical biology and translational activities. A cell biologist by training, Andy brings over 20 years of experience in drug discovery and development in autoimmune/inflammatory, oncology, and rare diseases. Andy was most recently VP, Biology at BridgeBio and some of its subsidiary companies.
Andy previously spent nine years at Gilead, most recently as leader of Gilead’s Inflammation and Oncology research and translational groups. He has led multiple programs in IBD and other indications through IND filing and nonclinical support through Phase 3 trials. He has also served as site head for Gilead in Seattle and Connecticut. He was previously one of the earliest staff at CGI Pharmaceuticals where he led the Inflammation and Autoimmune Disease, Biology and Informatics, and Bioinformatics teams for eleven years until its acquisition by Gilead.
He was a NSF postdoctoral fellow at the University of Geneva, Switzerland, where he studied the biology of intracellular membrane traffic. Andy holds a AB in Biochemistry from Harvard and PhD in Cell Biology from Yale School of Medicine (with Prof. Ira Mellman).